Topics

Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) Company Profile

05:06 EDT 17th September 2019 | BioPortfolio


News Articles [2025 Associated News Articles listed on BioPortfolio]

FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference

SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating p...

Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people bat...

Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Ph...

No-Cut CRISPR Halts Progression of Muscular Dystrophy in Mice

A CRISPR gene activation technique has been shown to prevent and reverse disease symptoms in a mouse model of muscular dystrophy. This no-cut CRISPR method increased the expression of the laminin-α1 ...

Genetics Home Reference: rigid spine muscular dystrophy

Source: National Library of Medicine - Related MedlinePlus Pages: Muscular Dystrophy

Discovery could lead to improved therapies for Duchenne muscular dystrophy

Researchers found that the protein sarcospan can play a major role in combating heart failure in patients with Duchenne muscular dystrophy.

Discovery points to innovative new way to treat Duchenne muscular dystrophy

Researchers have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease. The team restored muscle stem cell function that is im...

Global Duchenne Muscular Dystrophy Drugs Market Report, 2019-2025 – Mutation Suppression Displays the Potential to Grow at Over 40.2% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy Drugs – Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. ...

Drugs and Medications [59 Associated Drugs and Medications listed on BioPortfolio]

Succinylcholine chloride [renaissance lakewood llc]

Succinylcholine Chloride Injection USP, 20 mg/mL

Caprelsa [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use CAPRELSA safely and effectively. See full prescribing information for CAPRELSA.CAPRELSA (vandetanib) Tablets for Oral useInitial U.S. ...

Oxygen [weiler welding company]

OXYGEN, REFRIGERATED LIQUID

Caprelsa [genzyme corporation]

These highlights do not include all the information needed to use CAPRELSA safely and effectively. See full prescribing information for CAPRELSA.CAPRELSA (vandetanib) tablets, for oral useInitial U.S....

Prenate am [avion pharmaceuticals, llc]

PRENATE AM

PubMed Articles [2113 Associated PubMed Articles listed on BioPortfolio]

Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.

The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consist...

The importance of early diagnosis in LMNA-related muscular dystrophy for cardiac surveillance.

The identification of LMNA-related muscular dystrophy is important because it poses life-threatening cardiac complications. However, diagnosis of LMNA-related muscular dystrophy based on the clinical ...

Actininopathy - a new muscular dystrophy caused by ACTN2 dominant mutations.

To clinically and pathologically characterize a cohort of patients presenting with a novel form of distal myopathy and to identify the genetic cause of this new muscular dystrophy.

Muscle Percentage Index as a Marker of Disease Severity in Golden Retriever Muscular Dystrophy.

Golden retriever muscular dystrophy (GRMD) is a spontaneous X-linked canine model of Duchenne muscular dystrophy (DMD) that resembles the human condition. Muscle percentage index (MPI) is proposed as ...

The NIH Toolbox for cognitive surveillance in Duchenne muscular dystrophy.

We performed a prospective, cross-sectional cognitive assessment in subjects with Duchenne Muscular Dystrophy (DMD) and their biological mothers.

Clinical Trials [4684 Associated Clinical Trials listed on BioPortfolio]

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. Whi...

Ramipril Versus Carvedilol in Duchenne and Becker Patients

Data on preventive therapy in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) affected individuals without cardiac involvement are very limited and currently lacking ...

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

The purpose of this study is to determine if ACE-031 is safe and well-tolerated in children with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of sa...

A Study of TAS-205 for Duchenne Muscular Dystrophy

The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.

Safety Study of BLS-M22 in Healthy Volunteers

BLS-M22 is being developed as an anti-myotatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the...

Companies [3306 Associated Companies listed on BioPortfolio]

Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD)

Parent Project Muscular Dystrophy

Tivorsan Pharmaceuticals, Inc.

Tivorsan Pharmaceuticals, Inc. is a protein therapeutics company pioneering a unique approach to treating serious neuromuscular disorders, including DMD and Becker Muscular...

Prosensa Holding N.V.

Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on r...

Little Hercules Foundation and Team Joseph

Little Hercules Foundation is a registered, non-profit 501(c)(3) organization based in Dublin, Ohio. Little Hercules Foundation got its start in January 2013 when three moms, two ...

More Information about "Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD)" on BioPortfolio

We have published hundreds of Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) news stories on BioPortfolio along with dozens of Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) Clinical Trials and PubMed Articles about Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) Companies in our database. You can also find out about relevant Biotechnology Industry Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record